Abstract
The ring A and D substituted analogs of pentacyclic triterpenoid Lantadene A (1) and B (2) were synthesized and evaluated for in vitro anticancer activity against four human cancer cell lines (HL-60, MCF-7, A549 and HCT-116). Analogs 3, 4, 7 and 8 showed enhanced inhibitory activity as compared with 1 and 2. These analogs were found more active than standard drug cisplatin with selective toxicity towards cancer cells and were inactive against normal cells (VERO). Furthermore, the mechanistic studies to investigate the effects of the new compounds on Akt protein in lung cancer cell line A549 and the NF-κB signalling pathway suggested that the compounds may exert their inhibitory activity on cancer cells through inhibition of both Akt and NF-κB activation. The docking studies of most potent analog (7) with 3D crystal structure of the nuclear factor kappa-B (NF-κB) P50 homodimer (PDB ID: 1NFK) revealed that carbonyl group of ester side chain and C-28 carboxylic acid groups were mainly involved in hydrogen bonding interaction. The oleanane frameworks was involved in strong hydrophobic interaction with amino acid phenylalanine and structure of lead compound have the potential to be developed as potent NF-κB inhibitor and anticancer agent.
Keywords: Akt, Cytotoxicity, Docking, Lantadene, NF-κB.
Anti-Cancer Agents in Medicinal Chemistry
Title:Synthesis, Selective Cancer Cytotoxicity and Mechanistic Studies of Novel Analogs of Lantadenes
Volume: 13 Issue: 6
Author(s): Navin Kumar Tailor, Varun Jaiswal, San Swee Lan, Hong Boon Lee and Manu Sharma
Affiliation:
Keywords: Akt, Cytotoxicity, Docking, Lantadene, NF-κB.
Abstract: The ring A and D substituted analogs of pentacyclic triterpenoid Lantadene A (1) and B (2) were synthesized and evaluated for in vitro anticancer activity against four human cancer cell lines (HL-60, MCF-7, A549 and HCT-116). Analogs 3, 4, 7 and 8 showed enhanced inhibitory activity as compared with 1 and 2. These analogs were found more active than standard drug cisplatin with selective toxicity towards cancer cells and were inactive against normal cells (VERO). Furthermore, the mechanistic studies to investigate the effects of the new compounds on Akt protein in lung cancer cell line A549 and the NF-κB signalling pathway suggested that the compounds may exert their inhibitory activity on cancer cells through inhibition of both Akt and NF-κB activation. The docking studies of most potent analog (7) with 3D crystal structure of the nuclear factor kappa-B (NF-κB) P50 homodimer (PDB ID: 1NFK) revealed that carbonyl group of ester side chain and C-28 carboxylic acid groups were mainly involved in hydrogen bonding interaction. The oleanane frameworks was involved in strong hydrophobic interaction with amino acid phenylalanine and structure of lead compound have the potential to be developed as potent NF-κB inhibitor and anticancer agent.
Export Options
About this article
Cite this article as:
Tailor Kumar Navin, Jaiswal Varun, Lan Swee San, Lee Boon Hong and Sharma Manu, Synthesis, Selective Cancer Cytotoxicity and Mechanistic Studies of Novel Analogs of Lantadenes, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (6) . https://dx.doi.org/10.2174/18715206113139990127
DOI https://dx.doi.org/10.2174/18715206113139990127 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thermostable Subunit Vaccines for Pulmonary Delivery: How Close Are We?
Current Pharmaceutical Design Breath Analysis: The Approach Towards Clinical Applications
Mini-Reviews in Medicinal Chemistry Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Biomarkers in Non-Small Cell Lung Cancer: Perspectives of Individualized Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry Tyrosine Kinase Mutations in Human Cancer
Current Molecular Medicine LncRNA in Tumorigenesis Microenvironment
Current Bioinformatics 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Biosafety of Onco-Retroviral Vectors
Current Gene Therapy Coumarin Derivatives as Anticancer Agents for Lung Cancer Therapy: A Review
Anti-Cancer Agents in Medicinal Chemistry Posttranslational Regulation of O6-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers
Mini-Reviews in Medicinal Chemistry Acetogenin Extracted from <i>Annona muricata</i> Prevented the Actions of EGF in PA-1 Ovarian Cancer Cells
Protein & Peptide Letters Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design VEGF Signaling in Cancer Treatment
Current Pharmaceutical Design The Cross-over of Anticancer Agents with Osteoclast Activities
Current Cancer Therapy Reviews Chemistry and Biological Activity of [1,2,3]-Benzotriazine Derivatives
Current Organic Chemistry Molecular Predictors of Efficacy to Anti-EGFR Agents in Colorectal Cancer Patients
Current Cancer Drug Targets The De Novo Synthesis of Oligosaccharides: Application to the Medicinal Chemistry SAR-Study of Digitoxin
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Biotechnology Role of Graphene Nano-Composites in Cancer Therapy: Theranostic Applications, Metabolic Fate and Toxicity Issues
Current Drug Metabolism